Enabling Successful Sites, Ep3: Taking the complexity out of oncology clinical trials

Oncology clinical trials present unique challenges for investigative sites, including complex trial designs, challenging eligibility criteria, and invasive procedures. In addition, the oversaturation of trials leads to competition for patients and experienced sites.

The third episode of Enabling Successful Sites features a discussion between Karen McIntyre (Vice President, Global Site Alliances), Mitch Carter (Associate Director, Global Site Alliances), and Angela Galindo, (Vice President, Client Engagement at START Network) as they talk about the competition for patients and experienced sites for oncology trials, why a site would pass on a study opportunity and how we can make oncology studies less burdensome for both patients and sites.

 

Return to Insights Center

Related Insights

Podcast

Enabling Successful Sites, Ep2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training

Jun 28, 2024

Podcast

De-risking Drug Development | Episode 1: How to drive value in pre-clinical development

May 28, 2024

Playbook

Insights from the 2022 R&D Innovation Survey

Feb 17, 2023

Blog

Studying rare cancer patient populations using integrated genomic and real-world data

Aug 30, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Blog

Reducing technology burdens: How sponsors and CROs can empower sites

Feb 7, 2024

Article

4 Insights on decentralized trials for biotechs

Jul 1, 2021

Blog

Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression

Apr 23, 2024

Article

How a joined-up development strategy pays off for early-stage biotechs

May 19, 2021

Blog

Decentralized Trials: Considerations for Building a New Patient-Centric Model

May 13, 2021

Blog

Scientific Advances: Catalyst for Biotech Investment and Innovation in Clinical Development

Mar 12, 2024

Report

New Medicines, Novel Insights: Advancing Precision Oncology

May 14, 2024